INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Search

All disclosures

Every ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.

Results

Data sources
SEC Form 43h ago
House PTR3h ago
SEC 13F3h ago
Robinhood Chain3h ago

Results

20,303 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
15
KT
Kelley Shannon TGeneral Counsel
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$431K
1,077 sh
Nov 6, 2026Nov 6, 2026
traded Nov 6, 2026
+0dSEC Form 4

Evidence

Page 7 of 508
← PrevNext →
15
TF
Tan FionaChief Technology Officer
WWayfair Inc.
Open-market sale · 10b5-1 plan
SELL
$1.00M
8,000 sh
Nov 4, 2026
Nov 6, 2026
traded Nov 4, 2026
+2d
SEC Form 4

Evidence

14
JB
Jackson BenjaminPresident
ICEIntercontinental Exchange, Inc.
Open-market sale · 10b5-1 plan
SELL$71K
400 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

14
TS
Tamari ShaharDirector, COO
GLBEGlobal-E Online Ltd.
Open-market sale · 10b5-1 plan
SELL$627K
14.0K sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

14
FD
Fairbank Richard DDirector, Chairman and CEO
COFCAPITAL ONE FINANCIAL CORP
Open-market sale · 10b5-1 plan
SELL$2.01M
9,942 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

14
FD
Fairbank Richard DDirector, Chairman and CEO
COFCAPITAL ONE FINANCIAL CORP
Open-market sale · 10b5-1 plan
SELL$5.01M
24.6K sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

14
DN
Debbi NirDirector, President
GLBEGlobal-E Online Ltd.
Open-market sale · 10b5-1 plan
SELL$797K
17.9K sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

14
FD
Fairbank Richard DDirector, Chairman and CEO
COFCAPITAL ONE FINANCIAL CORP
Open-market sale · 10b5-1 plan
SELL$1.07M
5,315 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

14
PC
Pitigoi CosminChief Financial Officer
FLYWFlywire Corp
Open-market sale · 10b5-1 plan
SELL$122K
5,916 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

14
FD
Fairbank Richard DDirector, Chairman and CEO
COFCAPITAL ONE FINANCIAL CORP
Open-market sale · 10b5-1 plan
SELL$1.67M
7,798 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

14
FD
Fairbank Richard DDirector, Chairman and CEO
COFCAPITAL ONE FINANCIAL CORP
Open-market sale · 10b5-1 plan
SELL$3.79M
18.8K sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

14
FD
Fairbank Richard DDirector, Chairman and CEO
COFCAPITAL ONE FINANCIAL CORP
Open-market sale · 10b5-1 plan
SELL$1.05M
4,929 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

14
FD
Fairbank Richard DDirector, Chairman and CEO
COFCAPITAL ONE FINANCIAL CORP
Open-market sale · 10b5-1 plan
SELL$1.09M
5,454 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

14
TS
Tamari ShaharDirector, COO
GLBEGlobal-E Online Ltd.
Open-market sale · 10b5-1 plan
SELL$594K
13.4K sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$70K
120 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RE
Robinson ElliottDirector
HNGEHinge Health, Inc.
Open-market sale
SELL—
0 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$182K
310 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$139K
240 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$186K
320 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RE
Robinson ElliottDirector
HNGEHinge Health, Inc.
Open-market sale
SELL—
0 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
SF
Shimanovsky Boris F.EVP, Chief Technology Officer
ZIPZIPRECRUITER, INC.
Open-market sale · 10b5-1 plan
SELL$141K
30.0K sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

13
KT
Kelly Roland ThomasChief Legal Officer and GC
VELVelocity Financial, Inc.
Open-market sale · 10b5-1 plan
SELL$58K
3,200 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$186K
320 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$142K
237 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$183K
306 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$100K
167 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$184K
320 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$93K
160 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$215K
375 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$193K
330 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$89K
156 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RE
Robinson ElliottDirector
HNGEHinge Health, Inc.
Open-market sale
SELL—
0 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$127K
221 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$119K
200 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$180K
320 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$166K
280 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
PK
Patel Sanj KDirector, CHAIRMAN & CEO
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$135K
1,460 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$71K
120 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$159K
280 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$184K
320 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence